Adagrasib Demonstrates Promising Activity in KRAS G12C-Mutated Cancers

作者
Mark L. Fuerst
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:45 (13): 14-14
标识
DOI:10.1097/01.cot.0000945324.33577.d0
摘要

Mutated Cancers: Mutated CancersAdagrasib has clinical activity across a broad range of KRAS G12C-mutated tumors, including pancreatic and biliary tract cancers, with a manageable safety profile, according to updated data from the Phase II KRYSTAL-1 study presented at a 2023 ASCO Plenary Series. In the Phase I/II KRYSTAL-1 study, 63 patients with KRAS G12C-mutated solid tumors, including pancreatic ductal adenocarcinoma, biliary tract cancers, other gastrointestinal (GI), and non-GI tumors, were treated with adagrasib. Among 57 patients with measurable disease, overall response rate (ORR) was 35.1 percent, disease control rate was 86 percent, median duration of response was 5.3 months, median progression-free survival (PFS) was 7.4 months, and median overall survival (OS) was 14 months. “Tumor reductions were observed across multiple tumor types, and deep responses were seen for pancreatic, small bowel, ovarian, esophagus, unknown primary, and breast cancer,” said lead author Shubham Pant, MD, MBBS, Associate Professor in the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center. KRAS G12C mutations act as oncogenic drivers in a range of solid tumors, including 14 percent of patients with non-small cell lung cancer (NSCLC) and 3-4 percent with colorectal cancer, as well as in 1-3 percent with small bowel cancer, 1-3 percent with biliary tract cancer, and 1 percent with ovarian and endometrial cancer. Adagrasib is a covalent inhibitor of KRAS G12C that has been granted accelerated approval by the FDA for the treatment of KRAS G12C-mutated NSCLC, and has also been granted breakthrough therapy designation in combination with cetuximab for the treatment of patients with KRAS G12C-mutated colorectal cancer. Preliminary data from the Phase II cohort of KRYSTAL-1 evaluated adagrasib 600 mg twice daily in patients with previously treated GI tumors, and it demonstrated clinical activity and manageable safety with a median follow-up of 6.3 months. Pant reported updated data from this Phase II cohort of patients with KRAS G12C-mutated solid tumors, other than non-small cell lung cancer and colorectal cancer, with a median follow-up of 16.8 months. The median age of patients was 65; about 60 percent had ECOG 1 status. Tumor types included pancreatic adenocarcinoma (21 patients), biliary tract cancers (12 patients), appendiceal (10 patients), ovarian (5 patients), unknown primary (4 patients), gastroesophageal junction esophagus (4 patients), endometrial (3 patients), small bowel (3 patients), and breast and glioblastoma (1 patient each). Patients received a median of two lines of prior systemic anticancer therapy, but “it is also important to note that about one-third of the patients received three or more prior lines of treatment,” Pant clarified. Among 63 patients treated with adagrasib, 57 had measurable disease at baseline for the blinded independent central review. At the time of data cutoff, the confirmed ORR, the primary endpoint, was 35 percent and disease control rate was 86 percent. In pancreatic cancers, the confirmed ORR was 33.3 percent and the disease control rate was 81 percent. In patients with biliary tract cancers, 41.7 percent of patients had a confirmed ORR with the disease control rate of 91.7 percent. “In gynecological cancers, we had a robust response rate of 57.1 percent,” Pant stated. No responses were seen in patients with appendiceal cancers. This lack of response is fairly consistent with recent reports that RAS-mutated mucinous appendiceal cancers are relatively indolent tumors, he said. Most responses were seen by the first scan, with a median time to response of only 1.4 months and 12 patients still remain on treatment. The overall median PFS was 7.4 months and the median OS was 14 months. For pancreatic cancer, the median PFS was 5.4 months and the median OS was 8 months. For biliary tract cancers, the median PFS was 8.6 months and the median OS was 15.1 months. The most common treatment-related adverse events (TRAE) were nausea, diarrhea, fatigue, and vomiting, which were mostly Grade 1 and 2. There was one Grade 4 TRAE, which was febrile neutropenia, and no Grade 5 TRAEs. TRAEs led to a dose reduction in 39.7 percent of patients and dose interruptions in 44.4 percent of patients, but no TRAEs led to treatment discontinuation. “The KRYSTAL-1 cohort is the largest Phase II tumor-agnostic data set to evaluate KRAS G12C-mutated solid tumors, excluding NSCLC and colorectal cancer,” Pant noted. “Adagrasib monotherapy demonstrated clinically meaningful activity in a variety of KRAS G12C-mutated solid tumors for which no standard-of-care treatment option is available. The clinical activity of adagrasib in patients with pancreatic cancer and biliary tract cancer is noteworthy, as chemotherapy, as we know, has limited clinical activities in this patient population in the second-line setting. “Adagrasib monotherapy is well-tolerated and has a manageable safety profile. Most adverse events are Grade 1 and 2, and KRAS G12C-targeted agents may represent a novel tumor-agnostic treatment option for patients with solid tumors harboring a KRAS G12C mutation,” Pant concluded. Mark L. Fuerst is a contributing writer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
标致的如娆完成签到,获得积分10
1秒前
1秒前
细心的安雁完成签到,获得积分10
2秒前
水星逃逸完成签到 ,获得积分10
2秒前
安凉完成签到 ,获得积分10
2秒前
D哈哈完成签到,获得积分10
2秒前
大意的罡完成签到,获得积分10
2秒前
封小封完成签到,获得积分10
2秒前
方方完成签到,获得积分10
3秒前
相信明天会更好完成签到,获得积分10
3秒前
zh完成签到,获得积分10
5秒前
77完成签到 ,获得积分10
5秒前
xy完成签到 ,获得积分10
6秒前
半夏完成签到,获得积分10
6秒前
solution完成签到 ,获得积分10
6秒前
李基米德完成签到,获得积分10
6秒前
7秒前
xsss完成签到,获得积分10
7秒前
41完成签到,获得积分10
7秒前
诚心的小笼包完成签到 ,获得积分10
7秒前
安详墨镜完成签到 ,获得积分10
7秒前
成永福完成签到,获得积分10
8秒前
molihuakai的应助被昨夜风宸采纳,获得10
8秒前
281911480完成签到,获得积分10
8秒前
勤恳含之完成签到 ,获得积分10
9秒前
XX完成签到 ,获得积分10
10秒前
10秒前
不知道在干嘛完成签到,获得积分10
11秒前
程xx完成签到,获得积分10
11秒前
litn完成签到 ,获得积分10
11秒前
科研民工完成签到,获得积分10
11秒前
再生极强的-涡虫完成签到,获得积分10
13秒前
13秒前
娜比小新完成签到 ,获得积分10
13秒前
晚风完成签到,获得积分10
13秒前
wq完成签到 ,获得积分10
13秒前
moca完成签到,获得积分10
14秒前
研友_Zzaoqn完成签到,获得积分10
14秒前
千空完成签到 ,获得积分10
14秒前
郑一鸣完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809184
捐赠科研通 7776198
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479039